重组抗体
重组抗体，也称为基因工程抗体，是指通过DNA重组技术将抗体相应的基因序列根据需要进行改造和重组，并构建在质粒上，再通过蛋白外源表达技术将构建好的质粒转染/转化入适合的宿主细胞表达获得的抗体。换言之，重组抗体是通过将免疫特异性重链和轻链抗体克隆到高产的哺乳动物表达载体中而制成的。将得到的载体引入到表达宿主（如细菌、酵母或哺乳动物）中，用于生产高质量的功能性抗体。重组抗体很好的解决了动物源抗体引起的人体排斥反应，使得抗体实现人源化，使抗体的效能更为完善。
近年来，重组抗体的使用在治疗和诊断中变得越来越广泛。 与传统抗体相比具有显着优势，重组抗体变得越来越受青睐。最重要的一点是重组抗体可以最大化人源化以解决不同物种之间的异质性。
重组抗体可分为五大类：嵌合抗体、人源化抗体、全人源化抗体、小分子抗体、双特异性抗体。华美生物拥有近500种重组兔单克隆抗体，具有高纯度、亲和力强以及批次间偏差小等特点。
产品特色
华美生物可提供各种类型的重组抗体，包括全长抗体、scFv、Fab、sdAb、同种型/亚型和各种形式的 Fc 融合蛋白。
华美生物的重组抗体已在多个应用平台验证，包括 WB、IF、IHC、FC、IP、ELISA、GICA 和 Neutralising。
CD146 Antibody (CSB-RA013563A0HU)
Positive WB detected in A375 whole cell lysate. All lanes CD146 antibody at 0.6μg/mL.
GAPDH Antibody (CSB-RA009232A0HU)
Positive WB detected in U87 whole cell lysate, Mouse brain tissue. All lanes GAPDH antibody at 0.31μg/mL.
CD9 Antibody (CSB-RA004969A0HU)
Positive WB detected in U87 whole cell lysate. All lanes CD9 antibody at 0.55μg/mL.
CD31 Antibody (CSB-RA017767A0HU)
Positive WB detected in THP-1 whole cell lysate. All lanes CD31 antibody at 0.95μg/mL.
Histone H3.3 Antibody (CSB-RA010109A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:60, counter-stained with DAPI.
CD21 Antibody (CSB-RA005934A0HU)
Immunofluorescence staining of Raji cells with the antibody at 1:34, counter-stained with DAPI.
Histone H3.1 Antibody (CSB-RA010418A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:93, counter-stained with DAPI.
CD97 Antibody (CSB-RA004972A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:87.5, counter-stained with DAPI.
CD34 Antibody (CSB-RA004926A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system.
CD4 Antibody (CSB-RA004935A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human spleen tissue performed on a Leica BondTM system.
CD44 Antibody (CSB-RA004938A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system.
CD21 Antibody (CSB-RA005934A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system.
CD81 Antibody (CSB-RA004960A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD99 Antibody (CSB-RA004973A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD74 Antibody (CSB-RA004956A0HU)
Overlay histogram showing Raji cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD163 Antibody (CSB-RA801238A0HU)
Overlay histogram showing Raw264.7 cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
HDAC6 Antibody (CSB-RA010242A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA010242A0HU in HepG2 whole cell lysate.
Lane 2: CSB-RA010242A0HU (3μg) + HepG2 whole cell lysate (500μg)
Lane 3: HepG2 whole cell lysate (20μg)
CDC5L Antibody (CSB-RA858712A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA858712A0HU in Hela whole cell lysate.
Lane 2: CSB-RA858712A0HU (3μg) + Hela whole cell lysate (500μg)
Lane 3: Hela whole cell lysate (20μg)
BAK1 Antibody (CSB-RA624111A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA624111A0HU in HEK293 whole cell lysate.
Lane 2: CSB-RA624111A0HU (3μg) + HEK293 whole cell lysate (500μg)
Lane 3: HEK293 whole cell lysate (20μg)
ATM Antibody (CSB-RA618770A0HU)
Lane 1: Rabbit control IgG instead of CSB-RA618770A0HU in PC3 whole cell lysate.
Lane 2: CSB-RA618770A0HU (3μg) + PC3 whole cell lysate (500μg)
Lane 3: PC3 whole cell lysate (20μg)
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-S Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-S Antibody (CSB-RA33245A0GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with HCoV-OC43, HCoV-229E.
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-N Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-N Antibody (CSB-RA33255A0GMY) is specific for SARS-CoV-2-N protein, without any cross-reactivity with NL63-CoV, HCoV-OC43, HCoV-229E or HCoV-HKU1.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A1GMY) is clean, the detection limit can be as low as 125ng/mL (8.75ng/0.07mL), and the sensitivity is very good.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A2GMY) is clean, the detection limit can be as low as 15.625ng/ml (1.09ng/0.07ml), and the sensitivity is very good
Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by S Antibody (CSB-RA33245A1GMY) with the IC50 is 2.38 μg/Ml.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY)
This nanobody competitively prevented SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) from binding to ACE2-HRP conjugate (CSB-MP866317HU). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the nanobody concentrations. It showed that the nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of the nanobody is 0.1074 μg/mL.
产品列表
您可以在下述列表中寻找您所需要的产品，或直接在顶部搜索框中输入您需要查找的靶点、产品名称、货号。有任何问题，请点击此处在线咨询。
| 产品名称 | 货号 | 规格 |
|---|---|---|
| S Antibody | CSB-RA33245A1GMY | 100ul/50ul |
| N Antibody | CSB-RA33255A1GMY | 100ul/50ul |
| N Antibody, FITC conjugated | CSB-RA33255C1GMY | 100ul/50ul |
| N Antibody, Biotin conjugated | CSB-RA33255D1GMY | 100ul/50ul |
| S Antibody, FITC conjugated | CSB-RA33245C1GMY | 100ul/50ul |
| HMGB1 Antibody | CSB-RA439052A0HU | 100μl/50μl |
| FLNA Antibody | CSB-RA548809A0HU | 100μl/50μl |
| SSTR2 Antibody | CSB-RA827375A0HU | 100μl/50μl |
| TPBG Antibody | CSB-RA669019A0HU | 100μl/50μl |
| INS Antibody | CSB-RA584163A0HU | 100μl/50μl |
| KDM1A Antibody | CSB-RA222329A0HU | 100μl/50μl |
| AURKA Antibody | CSB-RA223479A0HU | 100μl/50μl |
| ALAS1 Antibody | CSB-RA266893A0HU | 100μl/50μl |
| LDLR Antibody | CSB-RA575353A0HU | 100μl/50μl |
| PDGFRB Antibody | CSB-RA213932A0HU | 100μl/50μl |
| MET Antibody | CSB-RA983271A0HU | 100μl/50μl |
| SLC2A1 Antibody | CSB-RA297401A0HU | 100μl/50μl |
| CD8A Antibody | CSB-RA934881A0HU | 100μl/50μl |
| MDK Antibody | CSB-RA276759A0HU | 100μl/50μl |
| PRMT5 Antibody | CSB-RA176962A0HU | 100μl/50μl |
关于重组抗体
与传统抗体相比，重组抗体的优势具体如下：
- 更高的一致性和重复性
因为重组抗体是由一组独特的基因发展而来的，所以抗体生产是可控且可靠的。可以避免杂交瘤细胞制备中的一些问题，如基因丢失、基因突变和细胞株漂移等。这使得抗体的批次间差异非常小，从而为您提供高度可重复的结果。
- 更高的灵敏度和特异性
利用重组技术，更容易通过抗体工程提高抗体特异性和灵敏度。所需克隆的选择过程发生在杂交瘤细胞和重组克隆阶段，这使我们能够选择最优的抗体质量。
- 易于扩展
随着抗体基因的分离，与传统单克隆技术相比，抗体表达能够以任何规模在更短的时间内进行。这意味着我们可以在数周而非数月内产生定制抗体。
- 无动物高通量生产
一旦分离出产生抗体的基因，就可以实现无动物体外生产。
